Details

Autor(en) / Beteiligte

• Gordon, Michael S.
• Mitchell, Shannon Gwin
• Blue, Thomas R.
• Vocci, Frank J.
• Fishman, Marc J.
• Murphy, Sean M.
• Couvillion, Kathy
• Maher, Kelly
• Ryan, Danielle
• Wenzel, Kevin
• Danner, Martha L.
• Jarvis, Daniel K.

Titel

A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail

Ist Teil von

• Journal of substance abuse treatment, 2021-09, Vol.128, p.108241-108241, Article 108241

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Applied Social Sciences Index & Abstracts (ASSIA)

Beschreibungen/Notizen

• This study is a randomized, open label, controlled trial of extended-release buprenorphine (XR-B; BRIXADI™ formulation) versus extended-release naltrexone (XR-NTX) in Maryland jails. A 7-site, open-label, equivalence design will randomly assign 240 adults with a history of opioid use disorder (OUD), stratified by gender and jail, who are nearing release to one of two treatment arms: 1) XR-B in jail or 2) XR-NTX in jail, both followed by 6 monthly injections postrelease at a community treatment program. The primary aim is to determine the rate of pharmacotherapy adherence (number of monthly injections received) of XR-B compared to XR-NTX. The proposed study is innovative because it will be the first randomized clinical trial in the U.S. assessing the effectiveness of receiving XR-B vs. XR-NTX in county jails. The public health impact of the study will be highly significant and far-reaching because most individuals with OUD do not receive treatment while incarcerated, thereby substantially raising their likelihood of relapse to drug use, overdose death, and re-incarceration. Understanding how to expand acceptance of medications for OUD in jails, particularly extended-release medications, and supporting treatment engagement and medication adherence in transition to the community, has far-reaching implications for improving treatment access and success in this population. •This study is one of the first in the US to randomize individuals in jail to injectable buprenorphine (XR-B, BRIXADI™).•The primary research question is to determine the effectiveness of XR-B versus XR-NTX in terms of pharmacotherapy adherence.•Understanding how to expand acceptance of extended-release medications in jail has far-reaching implications.